Research & Development
Blood biomarker in study predicts whether the cognitively healthy will develop Alzheimer’s
Astrocytes -- a subtype of glial cells that make up most cells in the human central nervous system -- may be the key driver of Alzheimer's disease progression, researchers said.
May 30, 2023
Alzheimer’s disease and modifiable risk factors: Genetic associations revealed
Novel genetic associations between increased Alzheimer’s disease risk and high HDL cholesterol and high systolic blood pressure were revealed in a study.
May 17, 2023
Quest Diagnostics extends Alzheimer's disease portfolio with AI-enabled test service
The RestoreU Dementia Panel employs artificial intelligence developed by uMethod to create personalized care plans aimed at helping physicians improve patient care while also satisfying cognitive care guidelines.
May 4, 2023
C2N Diagnostics announces study confirming accuracy of test for Alzheimer’s diagnosis
The study results show that the amyloid probability score (APS) as measured by the PrecivityAD test accurately reflects the amyloid pathology characteristic of progressive Alzheimer’s disease.
March 30, 2023
Study takes aim at blood test for multiple pathways implicated in Alzheimer's disease
The study may ultimately lead to more personalized patient care through the development of a blood test for multiple pathways implicated in the disease, the researchers said.
March 29, 2023
Roche, Lilly partner on early diagnosis of Alzheimer's disease
The firms are developing one of Roche's panels, which measures phosphorylated Tau (pTau) 181 protein and apolipoprotein (APOE) E4 in human blood plasma.
March 22, 2023
Rowan University, Durin Technologies tout preliminary results for early Alzheimer's blood test
Using eight autoantibody biomarkers, the test identified the presence of Alzheimer's disease pathology across the disease's progression, including among those originally determined to have no trace of the disease, the researchers said.
March 8, 2023
AriBio, Fujirebio partner on biomarker development for Alzheimer’s, other neurodegenerative disorders
The agreement will provide Fujirebio access to clinical samples and data that have been collected in an ongoing phase III Alzheimer’s disease study being conducted by AriBio.
March 8, 2023
Modifying messenger RNA provides new Alzheimer’s disease target
Reducing methylation of a key messenger RNA can promote macrophage migration into the brain and ameliorate Alzheimer’s disease symptoms in mice.
March 7, 2023
Analysis of genome-wide methylomic variations reveal epigenetic changes in Alzheimer’s brains
Multiple papers have already described DNA methylation differences associated with Alzheimer’s and other forms of dementia in several regions of the brain.
February 22, 2023
Blood biomarker facilitates vascular dementia diagnosis
In a study, researchers hypothesized that the body might respond to damaged small blood vessels with intensified efforts to grow more vessels, and they identified the signaling involved in the formation of new blood vessels.
February 23, 2023
Alzheimer’s disease testing firm C2N nabs additional $15M in financing
C2N will allocate part of the additional financing to support its new generation blood test, PrecivityAD2, designed to aid in the diagnosis of Alzheimer's disease.
February 17, 2023
Page 1 of 6